chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Shallowbreathing; Has to force  to breath in trough  his upper chest, have to breath deeply, breath hard / anything I do physically I have to sit-down for 10 minutes; Getting tired to go to the bathroom; This spontaneous case was reported by a consumer and describes the occurrence of HYPOPNOEA (Shallowbreathing), DYSPNOEA (Has to force  to breath in trough  his upper chest, have to breath deeply, breath hard / anything I do physically I have to sit-down for 10 minutes) and FATIGUE (Getting tired to go to the bathroom) in a 73-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027C21A and 040B21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included TRAZODONE, BUPROPION and PAROXETINE for an unknown indication.   On 15-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced HYPOPNOEA (Shallowbreathing), DYSPNOEA (Has to force  to breath in trough  his upper chest, have to breath deeply, breath hard / anything I do physically I have to sit-down for 10 minutes) and FATIGUE (Getting tired to go to the bathroom). At the time of the report, HYPOPNOEA (Shallowbreathing), DYSPNOEA (Has to force  to breath in trough  his upper chest, have to breath deeply, breath hard / anything I do physically I have to sit-down for 10 minutes) and FATIGUE (Getting tired to go to the bathroom) had not resolved.            Patient reported that symptoms started 1 week after the second dose and still ongoing after 2 months.  No information regarding treatment was reported by the patient.
Some of the vaccine leaked while administering; Syringe connection issue; This spontaneous case was reported by a health care professional and describes the occurrence of UNDERDOSE (Some of the vaccine leaked while administering) and DEVICE CONNECTION ISSUE (Syringe connection issue) in a 63-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 31-Mar-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 31-Mar-2021, the patient experienced UNDERDOSE (Some of the vaccine leaked while administering) and DEVICE CONNECTION ISSUE (Syringe connection issue). On 31-Mar-2021, UNDERDOSE (Some of the vaccine leaked while administering) and DEVICE CONNECTION ISSUE (Syringe connection issue) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported. No treatment information was provided.
2 month old died following routine vaccinations.  Medical examiner was Dr.  10/28/08 Autopsy report states COD & manner of death as undetermined.  10/28 Autopsy report also states patient found lying on side unresponsive in adult bed 2 hrs s/p laid down for nap.  Had fever s/p vaccination & received tylenol.  Findings at autopsy included viscous bronchial mucus & chronic cystitis.
This case was reported by a pharmacist via call center representative and described the occurrence of influenza-like symptoms in a patient who received SHINGRIX. On an unknown date, the patient received SHINGRIX at an unknown dose. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced influenza-like symptoms. On an unknown date, the outcome of the influenza-like symptoms was unknown. It was unknown if the reporter considered the influenza-like symptoms to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not applicable for this report. Adverse Event was collected from GlaxoSmithKline employee in Vaccine Inside Sales, call to the Regulatory Authority. The health care professional was not on the line. GlaxoSmithKline employee stated health care professional called and told her that a pharmacist was told by another pharmacist at work that people at church were discussing having flu-like symptoms following administration of SHINGRIX. No vaccine data, no patient data and no other information was available to Regulatory Authority at the reporting time.
Fever, redness, swelling at injection site. Only at site of KINRIX injection (DTaP/IPV).
beginning on 1/31/2021 at approximately 5:00pm I noticed joint pain in the elbow and hand/wrist of the arm the injection was given in. This joint pain progressed to then include muscle pain and by the morning of 2/1/2021 joint/muscle pain was not localized to one specific area of the body and I was experiencing nausea
20 hrs. after first dose of oral typhoid c/o headache, severe nausea, some vomiting, abd. cramping, fever 100-101 degrees lasting about 12 hrs. Called hotline at the hospital. Was told symptoms normal. Continue taking last pills which she did. Not dehydrated.
pt felt inc fatigue; 10OCT exp numbness in lips; during flight to Russia on 14OCT pt had severe h/a & body/muscle aches; thought had laryngitis because had dysphenia; 15OCT & 17OCT sore throat & dysphagia; devel swollen face w/paralysis;
0.5ml is given as a booster dose / What if the dose given for booster is 0.5ml; This spontaneous case was reported by a nurse and describes the occurrence of INCORRECT DOSE ADMINISTERED (0.5ml is given as a booster dose / What if the dose given for booster is 0.5ml) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On an unknown date, the patient experienced INCORRECT DOSE ADMINISTERED (0.5ml is given as a booster dose / What if the dose given for booster is 0.5ml). At the time of the report, INCORRECT DOSE ADMINISTERED (0.5ml is given as a booster dose / What if the dose given for booster is 0.5ml) had resolved.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. Treatment medications were not provided by the reporter.
Left arm has itchy, quarter sized and dime sized raised red welts over injection site. No resolution as of 2/17.
FLU SYMPTOMS-N/V,DIARRHEA, FEVER-101F. STATED ALREADY HAD GI BUG BACK IN NOV. 2006. WAS NOT VACCINATED FOR FLU THIS YEAR. SENT TO EMERGENCY DEPT TO R/O FLU. INFLUENZA WAS RULED OUT.
Fever, shivering, muscle pains, headache, upset stomach, weakness, tired.
wrong technique in product usage process; This spontaneous case was reported by a health care professional and describes the occurrence of WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (wrong technique in product usage process) in a 40-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Apr-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On 02-Apr-2021, the patient experienced WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (wrong technique in product usage process). On 02-Apr-2021, WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (wrong technique in product usage process) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications was provided. No laboratory details was provided. No treatment details was provided
hospitalized with COVID pneumonia after first dose; More than 36 days have passed since first dose/doctor told her to wait for 90 days for second dose; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of COVID-19 PNEUMONIA (hospitalized with COVID pneumonia after first dose) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    The patient's past medical history included No adverse event (No medical history reported.).  On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Jan-2021, the patient experienced COVID-19 PNEUMONIA (hospitalized with COVID pneumonia after first dose) (seriousness criteria hospitalization and medically significant). On an unknown date, the patient experienced OFF LABEL USE (More than 36 days have passed since first dose/doctor told her to wait for 90 days for second dose). The patient was hospitalized from 29-Jan-2021 to 18-Feb-2021 due to COVID-19 PNEUMONIA. At the time of the report, COVID-19 PNEUMONIA (hospitalized with COVID pneumonia after first dose) and OFF LABEL USE (More than 36 days have passed since first dose/doctor told her to wait for 90 days for second dose) outcome was unknown.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.  No treatment information was provide. Patient was told to wait 90 days to receive the second dose by her doctor. This report refers to a case of Off label use for mRNA-1273, lot # 013L20A with an associated AE. Based on the current available information, the mRNA-1273 does not contain a virus capable of causing infection and with the occurrence of COVID-19 Pneumonia after vaccination, this event is assessed as unlikely related to mRNA-1273.; Sender's Comments: This report refers to a case of Off label use for mRNA-1273, lot # 013L20A with an associated AE. Based on the current available information, the mRNA-1273 does not contain a virus capable of causing infection and with the occurrence of COVID-19 Pneumonia after vaccination, this event is assessed as unlikely related to mRNA-1273.
Premature rupture of membranes in otherwise uncomplicated pregnancy - membranes ruptured on 11/23, child delivered via vaginal induction, original due date 11/29/23. Child later went on to develop partial seizures at 4 months of age and infantile spasms at 6 months of age. Cause of seizures has not been determined to date despite extensive workup.
Beginning 5:00 pm on the date of vaccination, I experienced 100.4 F fever, severe body aches, headache, and chills lasting over 30 hours. Symptoms are improving, but still present.
Seizure at home; immediately taken to the hospital. Seizure lasted after arrival to hospital; unknown duration, temp 102 degrees F. Had low temperature mom stated since immunization. Treated with IV's, KT, Rocephin given at hospital. 60 day follow up on 11/04/2003: "Unknown if vaccine recipient did ever recover from adverse events.  Still having seizures, was seen by neurologist.  He says will out grow. Doing much better." Discharge Summary received on 10/17/2003 states otitis media.
This spontaneous report as received from a certified medical assistant refers to a patient of unknown age and gender. The medical assistant reported that the patient received the 1st dose of GARDASIL (dose and route not reported) on 25-OCT-2012, the 2nd dose of GARDASIL (dose and route not reported) on 06-MAY-2014 and was in the office "today", 22-AUG-2014, to receive the 3rd dose of GARDASIL (dose and route not reported). No adverse effects reported. Additional information has been requested.
As of disease investigation on 8/23/21 case reported symptom onset of 8/14/21 which included fever, chills, runny nose, new olfactory disorders, fatigue and cough. Still symptomatic.
Pain in L shoulder increasing after the first hour until unable to move r/t pain that evening.  The pain has been slow to resolve over 3 weeks without treatment.
Fever & Diarrhea Narrative: Low grade fever and diarrhea day after injection. Resolved by next day.
SHORTNESS OF BREATH; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. The patient's past medical history included COPD. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805018, and expiry: UNKNOWN) dose was not reported, administered on 06-MAR-2021 for prophylactic vaccination on left arm. No concomitant medications were reported.  On 06-MAR-2021, the subject experienced shortness of breath. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from shortness of breath. This report was non-serious.
Swelling and blisters on tongue. Patient visited PCP and started MEDROL 4mg Dosepak on 2/28/17.
I started running a low grade temp about 9 pm on 1/6/2021. Woke in a.m. (early) with 100.9 temp and swollen lymph nodes under my arm and along the side of my breast and a tingly right hand. Fever broke early am on friday (1/8/2021). I was very fatigued and tired and still had a very tingly hand on 8th. Tingly slowly got better and I didn't notice it anymore on Wednesday ,13th.  Fatigue was better by Sunday the 1/9th. I felt pretty much back to normal by 11th except for my hand. No treatment.
That following morning around 4AM, I woke up because my heart was beating very fast. I was going way to fast and then I fell asleep and awoke at 6AM feeling it again. I went to work ignoring the pain, but I was scared. I had this happen before on my first booster that had me hospitalized. I called my cardiologist and sent me to the ER. They lowered my heartbeat but couldn't release me and I was admitted for another day. My blood pressure was very low and the medications they gave me made it lower. I stayed in the Hospital one day. Now I have to continue medications because I am at a high risk for stroke. My PCP and Cardiologist now have me as high risk. They and I know it was because of the booster.
Blood clot, Pulmonary Embolism diagnosis Shortness of breathe Back Pain
Per wife states husband complained of a nose bleed around 8:30pm.  Nose bleed did not stop so they went to ER around 9pm. While at hospital, BP was 227/128. Pt was given several doses of Clonidine to stabalize BP.  Eventually nose bleed did reduce and pt was discharged home with a rx for Clonidine and Amoxil.
some blood problems around the heart; This spontaneous case was reported by a consumer and describes the occurrence of BLOOD DISORDER (some blood problems around the heart) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced BLOOD DISORDER (some blood problems around the heart). At the time of the report, BLOOD DISORDER (some blood problems around the heart) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications details were not reported by the reporter. Treatment details was not reported by the reporter.  Patient mentions Moderna has been link to some blood problems around the heart   This case was linked to MOD-2022-437569, MOD-2022-437577, MOD-2022-437756, MOD-2022-437770 (Patient Link).
hematoma; Injection site pain / Injection site soreness; Injection site swelling; Black and blue down the injected arm from the shoulder down to just past the elbow; This case was reported by a consumer via call center representative and described the occurrence of hematoma in a 84-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously experienced adverse reactions included heart valve replacement and chickenpox. Concomitant products included warfarin sodium (Coumadin).   On 2nd December 2019, the patient received the 1st dose of Shingrix (intramuscular). On 2nd December 2019, less than a day after receiving Shingrix, the patient experienced hematoma, injection site pain, injection site swelling and skin discoloration. The patient was treated with lidocaine hydrochloride (Lidocaine) and non-drug therapy (Ice Pack (No Medication)). On an unknown date, the outcome of the hematoma, injection site pain, injection site swelling and skin discoloration were not recovered/not resolved.   It was unknown if the reporter considered the hematoma, injection site pain, injection site swelling and skin discoloration to be related to Shingrix.  Additional case details were reported as follows: The patient received Shingrix and experienced injection site reaction consisting of pain, swelling, and soreness. The patient reports that she needed to go to the emergency department reporting black and blue down the injected arm from the shoulder down to just past the elbow. The ER physician diagnosed a hematoma, and recommended ice packs and lidocaine patches. Events have not improved at time of report. The reporter consented to follow up. Emergency room visit required.
Urticaria. Neomycin clipped into vaccine, unbeknownst to me.
This spontaneous report as received from a registered nurse refers to a 5 year old male patient. The patient was administered ATTENUVAX (Enders-Edmonston) on 02-APR-2008, then administered MUMPSVAX (dose number, units, route of administration, anatomical location, lot number were not reported), then RUBELLA on 07-MAY-2008, then the patient was revaccinated with M-M-R II (dose number, units, route of administration, anatomical location, lot number were not reported) on 11-AUG-2011. No adverse effects reported. Additional information is not expected because the reporter do not wish to be contacted.
Injection site days from injection date became red, hot to the touch and itchy. Injection site appeared like a giant mosquito bite, measured w a ruler to be 3.5 in in diameter. Consulted w  physician who said this to be a delayed allergic reaction
This spontaneous report was received from a pharmacist, via a company representative, concerning 3 female patients of unknown age. The patients' concurrent conditions, medical history, concomitant therapies, drug reactions and allergies were not reported. On an unknown date, the patients were vaccinated with PNEUMOVAX 23, intramuscular for prophylaxis (strength, dose, anatomical location, lot/batch # and expiration date were not reported). On multiple unspecified dates, after the administration of PNEUMOVAX 23, the three patients experienced redness, swelling and warmth at the injection site. The patients sought for medical attention, but it was unknown if treatment, laboratory diagnostics, or studies were performed for the events. The outcome of the events was unknown. The reporter did not provide a causal relationship between therapy with PNEUMOVAX 23, and the events vaccination site erythema, vaccination site warmth and vaccination site swelling.
rash at injection site; This case was reported by a physician via sales rep and described the occurrence of injection site rash in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced injection site rash. On an unknown date, the outcome of the injection site rash was recovered/resolved.   It was unknown if the reporter considered the injection site rash to be related to Shingrix.  Additional details were provided as follows:  The age at vaccination was not reported. The patient developed a rash at the injection site after her 2nd dose of Shingrix. The patient reported it to medical assistant in physician office.
Pt c/o "so sore that I cannot move arm". Denies paresthesias in hand.
patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 71-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.   It was reported that there had been no power outages that would have impacted the Moderna vaccine. However, the Healthcare professional reiterates that because facility was unable to download the digital data logger, they would need to treat this issue as a temperature excursion. The data logger was unable to download for the months of Dec-2021, Jan-2022, and Feb-2022. They were filling out a temperature excursion assessment with the State at that time. No adverse event was reported. Treatment information was not provided.
deltoid muscle pain/soreness (5/10 in severity). On 2nd day post vaccination, site (left deltoid) became erythematous with area of erythema extended radially from injection site approximately 5-7 cm on all sides.  Skin was warm and felt slightly tense. There was also a pink streak on medial anterior aspect of left deltoid extending toward axilla.  Compared to contralateral deltoid affected side was noticeably larger/more swollen
Upper lip swelling 3 hour after Immun.  Gave BENADRYL - No further swelling within next 1 hour.  No respiratory distress.
pink eye; fatigue; slight nasal congestion; This is a spontaneous report received from a non-contactable reporter (Consumer).  A 21 year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunization. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: CONJUNCTIVITIS (non-serious), outcome "unknown", described as "pink eye"; FATIGUE (non-serious), outcome "unknown", described as "fatigue"; NASAL CONGESTION (non-serious), outcome "unknown", described as "slight nasal congestion".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021580089 same report/drug/AE, different patient